StackRanksFinance newsletter earnings, ranked by estimated MRR
Public revenue estimates for tracked finance newsletters.
| Rank | Publication | MRR | ARR | YoY |
|---|
Public revenue estimates for tracked finance newsletters.
| Rank | Publication | MRR | ARR | YoY |
|---|
Tracked Publication
Biotech Investing Newsletter: 2x your money, one biotech catalyst at a time A biotech analyst (ex-Deutsche Bank, ex-consulting, PhD) dissects biotech catalysts worth investing in!
Earnings Estimates (Gross MRR)
Subscriber Composition
Composition not available yet
Subscriber mix will appear here once we have enough snapshot data for this publication.
Revenue Estimates (Gross MRR)
$248.4Range $82.8 – $819.7
Free Subscribers
No subscriber history yet
Free subscriber trends will appear here once we have enough monthly snapshots.
Paid Subscribers (est.)
30Post Activity
3 posts/moMedian Engagement per Post
Reactions
5
over 33 posts
Comments
0
over 33 posts
Restacks
2
over 33 posts
Paid Plans
Recent Posts
A failure of clinical trial design + where we probably went wrong and the paper that could have given the clue to the negative readout 15 months ago + where do we go from here
+ we ‘back-of-the-envelope’ run the VAV1 milestone payments + what it means for the upcoming earnings update
Access link inside
A piece arguing that Substack “will collapse” went viral last week. It’s a compelling read. In our sector of finance, it’s very likely wrong.